These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Given these uncertainties, the Company is unable to provide assurance that operations can be maintained as planned prior to the COVID-19 pandemic. These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on our business including with respect to our clinical trials including site initiation, patient enrollment and timing and adequacy of clinical trials on regulatory submissions and regulatory reviews and approvals of our product candidates pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution sale of and demand for our products our liquidity and availability of capital resources customer demand for our products and services customers’ ability to pay for goods and services and ongoing availability of an appropriate labor force and skilled professionals. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. For more information, visit and follow us on LinkedIn.Ĭertain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.
![jmp securities jmp securities](https://www.jmpg.com/wp-content/uploads/shutterstock_99828956x2-cropped.jpg)
The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Our licensees market their products in the U.S. and around the world. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut syndrome. Aquestive has five commercialized products on the U.S.
![jmp securities jmp securities](https://revelers.com/wp-content/uploads/2019/10/JMP_002-1000x600.jpg)
We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. For additional Company information, please visit and follow us on Twitter and LinkedIn.Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. PolyPid’s lead product candidate D-PLEX 100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Investors interested in meeting with PolyPid during the conference should contact their JMP representative. JMP Securities 2022 Life Sciences Conference: